MARKET

SLP

SLP

Simulations Plus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.48
+0.31
+0.77%
After Hours: 40.48 0 0.00% 16:00 09/21 EDT
OPEN
40.38
PREV CLOSE
40.17
HIGH
40.98
LOW
39.80
VOLUME
458.01K
TURNOVER
--
52 WEEK HIGH
90.92
52 WEEK LOW
39.80
MARKET CAP
814.98M
P/E (TTM)
71.07
1D
5D
1M
3M
1Y
5Y
BRIEF-Simulations Plus Releases ADMET Predictor (X.3)
reuters.com · 6d ago
Simulations Plus Releases ADMET Predictor® (X.3)
LANCASTER, Calif., September 15, 2021--Simulations Plus releases ADMET Predictor 10.3 (APX.3) with key upgrades to its AIDD Module making it the premier program for AI-driven drug design.
Business Wire · 6d ago
Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences
LANCASTER, Calif., September 08, 2021--Simulations Plus will be presenting at BofA Securities Tech Solutions for Drug Discovery and Oppenheimer Fall Healthcare Life Sciences conferences.
Business Wire · 09/08 12:30
Shoul You Keep Investing in Simulations Plus (SLP)?
Polen Capital, an investment management firm, published its “Polen U.S. Small Company Growth” second quarter 2021 investor letter – a copy of which can be downloaded here. A return of 13.47% was delivered by the fund for the second quarter of 2021, outperf...
Insider Monkey · 09/07 17:43
Ranger Investment Management, L.P. Buys Phreesia Inc, Cardlytics Inc, nLight Inc, Sells Magnite ...
GuruFocus News · 08/24 17:38
Simulations Plus' (NASDAQ:SLP) Returns On Capital Not Reflecting Well On The Business
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...
Simply Wall St. · 08/20 16:55
Simulations Plus Reports Received Second Phase Of Experimental Results From Collaborative Research Deal With A Large Pharma Co. To Evaluate Impact Of New AI-Driven Drug Design Module In ADMET Predictor
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has received the second phase of experimental
Benzinga · 08/19 12:43
BRIEF-Simulations Plus Reports Continued Success In Second Phase Of Aidd Collaboration With Large Pharmaceutical Company
reuters.com · 08/19 12:36
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLP. Analyze the recent business situations of Simulations Plus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLP stock price target is 64.67 with a high estimate of 75.00 and a low estimate of 54.00.
EPS
Institutional Holdings
Institutions: 235
Institutional Holdings: 15.01M
% Owned: 74.55%
Shares Outstanding: 20.13M
TypeInstitutionsShares
Increased
80
1.98M
New
27
232.57K
Decreased
53
610.08K
Sold Out
27
262.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.38%
Healthcare Equipment & Supplies
+0.22%
Key Executives
Chairman/Director
Walter Woltosz
Chief Executive Officer
Shawn O'Connor
Chief Financial Officer/Secretary
William Frederick
Corporate Executive
John DiBella
Independent Director
Lisa LaVange
Independent Director
John Paglia
Independent Director
David Ralph
Independent Director
Daniel Weiner
Declaration Date
Dividend Per Share
Ex-Div Date
07/12/2021
Dividend USD 0.06
07/23/2021
04/12/2021
Dividend USD 0.06
04/23/2021
01/11/2021
Dividend USD 0.06
01/22/2021
10/13/2020
Dividend USD 0.06
10/23/2020
07/09/2020
Dividend USD 0.06
07/24/2020
04/09/2020
Dividend USD 0.06
04/23/2020
01/09/2020
Dividend USD 0.06
01/24/2020
10/14/2019
Dividend USD 0.06
10/24/2019
07/10/2019
Dividend USD 0.06
07/24/2019
04/09/2019
Dividend USD 0.06
04/23/2019
01/09/2019
Dividend USD 0.06
01/24/2019
10/22/2018
Dividend USD 0.06
10/31/2018
07/06/2018
Dividend USD 0.06
07/25/2018
04/09/2018
Dividend USD 0.06
04/24/2018
01/16/2018
Dividend USD 0.06
01/25/2018
11/01/2017
Dividend USD 0.06
11/10/2017
07/18/2017
Dividend USD 0.05
07/26/2017
04/26/2017
Dividend USD 0.05
05/04/2017
01/20/2017
Dividend USD 0.05
01/26/2017
10/31/2016
Dividend USD 0.05
11/08/2016
  • All
  • Financials
  • Insiders
More
About SLP
Simulations Plus, Inc. is a developer of drug discovery and development software for mechanistic modeling and simulation, for machine-learning-based prediction of properties of molecules from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. The Company offers its products and services through two business segments, which include Simulations Plus, Inc. and Cognigen Corporation. Cognigen Corporation is the subsidiary of the Company. Its pharmaceutical/chemistry software is used by various companies, such as pharmaceutical, biotechnology, agrochemical, and food industry companies and to regulatory agencies for use in the conduct of industry-based research. Its clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamics modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions.

Webull offers kinds of Simulations Plus Inc stock information, including NASDAQ:SLP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLP stock methods without spending real money on the virtual paper trading platform.